GlassScriptPhysician profile
Michael J Jacobson
NPI 1013959188
$130,957.51
in general payments reported to CMS, 2019-2025
12 companies · $45K in 2025
The $45K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,737 · 2022: $14K · 2023: $14K · 2024: $53K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $59K · Honoraria: $34K · Travel and Lodging: $13K · Food and Beverage: $6,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $58,594.04 |
| Honoraria | $34,000.00 |
| Travel and Lodging | $13,164.35 |
| Food and Beverage | $6,631.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $128,031.38 | 2021-2025 | Inspire |
| Zoll Respicardia, INC. | $2,063.41 | 2023-2025 | Remede System |
| Janssen Pharmaceuticals, INC | $287.92 | 2023-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Mml US, INC. | $240.03 | 2024 | Reactiv8 |
| Astrazeneca Pharmaceuticals LP | $120.71 | 2021 | |
| Axsome Therapeutics, INC. | $56.43 | 2025 | Sunosi, Auvelity |
| Genentech USA, INC. | $46.07 | 2023-2024 | Xolair |
| Harmony Biosciences LLC | $45.72 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.35 | 2022 | |
| Insmed, INC. | $17.99 | 2025 | Brinsupri, Arikayce |
| Otsuka America Pharmaceutical, INC. | $14.14 | 2021 | |
| Apria Healthcare LLC | $13.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.